A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
=== SIRV model === The Susceptible-Infectious-Recovered-Vaccinated model is an extended SIR model that accounts for vaccination of the susceptible population. This model uses the following system of differential equations:
9 February – The New Zealand Government announces plans to revise the Active Investor Plus visa to attract more wealthy investors. 10 February: Driven by "pollution, degraded waterways, and over-allocation of water", Ngāi Tahu begins proceedings in the High Court against the Crown. The tribe argues that it has never lost rangatiratanga (sovereignty, or the right to exercise authority) over freshwater, but control has been encumbered by the Crown. The Crown's argument is that it has the right to control freshwater through the Resource Management Act 1991 and other acts. The lawsuit has been given the name "Tau v AG", with historian Te Maire Tau as the lead plaintiff, and the Attorney-General (currently Judith Collins) representing the Crown. ACT leader David Seymour drives a Land Rover up the New Zealand Parliament's steps as part of a fundraiser for a heart valve development programme at the University of Auckland. The Director of the Public Health Agency Nicholas Jones resigns. 11 February – The Australian company Millari Group announces plans to acquire and reopen Juken's former Gisborne saw mill, which closed in late 2023. 12 February: The Whangārei District Council led by Mayor Vince Cocurullo reiterates its refusal to comply with an order by Director-General of Health Diana Sarfati to fluoridate its water supply. The Salvation Army releases its annual State of the Nation report, which identifies food insecurity, unaffordable housing and domestic violence against children as major issues facing New Zealand in 2025.
=== Photochromic compounds === Photochromic compounds have the ability to switch between a range or variety of colors. Their ability to display different colors lies in how they absorb light. Different isomeric manifestations of the molecule absorbs different wavelengths of light, so that each isomeric species can display a different color based on its absorption. These include photoswitchable compounds, which are proteins that can switch from a non-fluorescent state to that of a fluorescent one given a certain environment. The most common organic molecule to be used as a photochrome is diarylethene. Other examples of photoswitchable proteins include PADRON-C, rs-FastLIME-s and bs-DRONPA-s, which can be used in plant and mammalian cells alike to watch cells move into different environments.
Sources: en.wikipedia.org
== Early life and education == Crick was the first son of Harry Crick and Annie Elizabeth Crick (née Wilkins). He was born on 8 June 1916 and raised in Weston Favell, then a small village near the English town of Northampton, in which Crick's father and uncle ran the family's boot and shoe factory. His grandfather, Walter Drawbridge Crick, an amateur naturalist, wrote a survey of local foraminifera (single-celled protists with shells), corresponded with Charles Darwin, and had two gastropods (snails or slugs) named after him. At an early age, Francis was attracted to science and what he could learn about it from books. As a child, he was taken to church by his parents. But by about age 12, he said he did not want to go any more as he preferred a scientific search for answers over religious belief. Walter Crick, his uncle, lived in a small house on the south side of Abington Avenue; he had a shed at the bottom of his little garden where he taught Crick to blow glass, do chemical experiments and to make photographic prints. When he was eight or nine he transferred to the most junior form of the Northampton Grammar School, on the Billing Road. This was about 1.25 mi (2 km) from his home so he could walk there and back, by Park Avenue South and Abington Park Crescent, but he more often went by bus or, later, by bicycle. The teaching in the higher forms was satisfactory, but not as stimulating. After the age of 14, he was educated at Mill Hill School in London (on a scholarship), where he studied mathematics, physics, and chemistry with his best friend John Shilston.
=== Approval history === On 22 December 2009, a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted 9–5 against approval of the drug based on concerns over both efficacy and safety, particularly the findings of mammary gland tumors of female rats. On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered "marginal". On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes. On 27 June 2012, the FDA approved lorcaserin for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who had at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). On 15 July 2016, the FDA approved the extended release version of lorcaserin for weight management with once-daily dosing instead of twice daily dosing. On 17 September 2020, the FDA withdrew approval for lorcaserin and for extended-release lorcaserin tablets.
Both Portal games take place in the fictional "Aperture Science Computer Aided Enrichment Center". Aperture Science was founded by Cave Johnson (voiced by J.K. Simmons) and originally sought to make shower curtains for the military. Its research happened upon the discovery of portal technology, and soon became a direct competitor with Black Mesa Research Facility (from the Half-Life series) for government funding. Johnson acquired the rights to a disused salt mine in the Upper Peninsula of Michigan, where they started building a labyrinthine set of offices, laboratories, facilities, and test chambers. During this time, Johnson became poisoned from exposure to moon dust, a key component of the paint needed to support portal technology, and became increasingly deranged. In Portal 2, the player explores these long-abandoned areas of Aperture, learning that the company had moved from testing on the country's finest, to paid volunteers, who were often homeless, and ultimately to coercing its own employees to participate in testing. Leading up to his death, Johnson ordered his lifelong assistant Caroline (voiced by Ellen McLain) to be the first test subject for a mind-to-computer transfer; her personality would ultimately form the core of GLaDOS (also McLain). Some time after Johnson's death, the old sections of the facility were vitrified, and a more modern facility was built atop the ruins.
== Warnings/Precautions == Pancreatitis has been reported in clinical trials, do not continue usage if any pancreatitis has been spotted or confirmed, other therapies should be considered in patients with a prior history of pancreatitis Hypoglycemia has been noted when used in combination with an insulin secretagogue or insulin, consider lowering the usage of insulin in order to reduce the risk of hypoglycemia Hypersensitivity reactions such as anaphylactic reactions and angioedema have occurred; in this case discontinue Trulicity/dulaglutide and seek medical advice Acute kidney injury, monitor the renal function in patients with renal impairment and report severe gastrointestinal reactions Severe gastrointestinal disease, as usage may sometimes be associated with severe gastrointestinal reactions. (Source)
Sources: en.wikipedia.org
Cetshwayo was captured a month after his defeat, and then exiled to Cape Town. The British passed rule of the Zulu kingdom onto 13 "kinglets", each with his own subkingdom. Conflict soon erupted between these subkingdoms, and in 1882, Cetshwayo was allowed to visit England. He had audiences with Queen Victoria and other famous personages before being allowed to return to Zululand to be reinstated as king. In 1883, Cetshwayo was put in place as king over a buffer reserve territory, much reduced from his original kingdom. Later that year, however, Cetshwayo was attacked at Ulundi by Zibhebhu, one of the 13 kinglets. Cetshwayo was wounded and fled. Cetshwayo died in February 1884, possibly poisoned. His son, Dinuzulu, then 15, inherited the throne. The academic Roberto Breschi notes that Zululand had a flag from 1884 to 1897 but this is pure conjecture as A.P. Burgers notes in his book. It consisted of three horizontal bands in equal width of gold, green and red.
=== Spin column === Spin column-based nucleic acid purification is a method of purifying DNA, RNA or plasmid from a sample using a spin column filter. The method is based on the principle of selectively binding nucleic acids to a solid matrix in the spin column, while other contaminants, such as proteins and salts, are washed away. The conditions are then changed to elute the purified nucleic acid off the column using a suitable elution buffer.
Additionally, several types of ubiquitination events parallel and complement the galectin-driven processes: Ubiquitination of TRIM16-ULK1-Beclin-1 stabilizes these complexes to promote autophagy activation as described above. ATG16L1 has an intrinsic binding affinity for ubiquitin; whereas ubiquitination by a glycoprotein-specific FBXO27-endowed ubiquitin ligase of several damage-exposed glycosylated lysosomal membrane proteins such as LAMP1, LAMP2, GNS/N-acetylglucosamine-6-sulfatase, TSPAN6/tetraspanin-6, PSAP/prosaposin, and TMEM192/transmembrane protein 192 may contribute to the execution of lysophagy via autophagic receptors such as p62/SQSTM1, which is recruited during lysophagy, or other to be determined functions.
== External links == "Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-10-25. Neuropeptide+Y+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Causes == A spontaneous spinal CSF leak refers to any CSF leak that has not been preceded by a surgical or other medical procedure. Later evidence suggests that these leaks result from either a discogenic pathology, such as microspur, osteophyte or spinal disc herniation that pierces the dura like a knife, connective tissue disorder (which can often lead to discogenic pathology), or spinal drainage problems. A cerebrospinal fluid leak can be a rare complication of an anterior cervical discectomy and fusion. One study suggested a CSF leak to follow from 0.5% of operations. Another study suggests a CSF leak to follow from 1% of operations. In most of these cases repair is successful.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.